卡培他滨对复发转移三阴性乳腺癌患者的治疗作用  

Curative effect of capecitabine maintenance therapy on the recurrence and metastasis of triple - negative breast cancer

作　　者：李林[1] 王楠[1] 秦威[1] 朱明智[1] 陈卓[1] 王芳[1] 郭广成[1] 熊有毅 谷元廷[1] 李建华[2] 

机构地区：[1]郑州大学第一附属医院乳腺外科,450052 [2]郑州大学第一附属医院甲状腺外科,450052

出　　处：《中华实验外科杂志》2017年第9期1552-1554,共3页Chinese Journal of Experimental Surgery

摘　　要：目的 探讨卡培他滨对复发转移三阴性乳腺癌维持治疗的疗效。方法 选取我院60例复发转移三阴性乳腺癌患者，随机分为实验组和对照组各30例，实验组在治疗期间使用含有卡培他滨的联合化疗方案且治疗有效，在联合化疗结束后继续卡培他滨维持治疗至疾病再次进展，对照组在治疗有效且病情稳定后停止化疗，统计两组患者的有效率、至病情再次进展的时间、用药期间的不良反应。 结果 实验组的有效率（50.0%）明显高于对照组（40.0%），差异有统计学意义（P＝0.039）；实验组的维持治疗时间为2.3～19.3个月，平均维持治疗时间为6.6个月，中位无进展生存期（PFS）为10.6个月。对照组至病情再次进展的时间为4.3个月，两组患者的至病情再次进展的时间差异有统计学意义（P＝0.026）；实验组患者在维持治疗的不良反应主要为骨髓抑制、肝肾功能损害、手足综合征、消化道反应等，36.6%的患者出现骨髓抑制，40.0%的患者出现肝肾功能损害，46.7%的患者出现手足综合征，60.0%的患者出现消化道反应。 结论 卡培他滨作为复发转移三阴性乳腺癌维持治疗方法可以有效改善患者的症状，延缓病情的进展。Objective To study the maintenance treatment curative effect of capecitabine chemotherapy on recurrent triple-negative breast cancer patients. Methods From December 2012 to December 2014, 60 cases of recurrent triple-negative breast cancer were studied, and randomly divided into experimental group and control group （n=30 each）. In the experimental group, the patients were treated with a combination chemotherapy regimen containing capecitabine during the rescue treatment and the curative efficacy was effective, and after complete of the combination chemotherapy capecitabine was ginve continuously to recurrence of the disease progression. In the control group, the chemotherapy was stopped after the rescue treatment was effective and the condition was stable. The effective rate, the time to the disease progression and the adverse reactions were statistically analyzed.Results The effective rate in the experimental group （50.0%） was significantly higher than in the control group （40.0%, P=0.039）. The maintenance treatment time in the experiental group was 2.3-19.3 months （mean 6.6 months）, and the median progression-free survival （PFS） was 10.6 months. In the control group, the time to the disease progression was 4.3 months. There was significant difference in the time to the disease progress between two groups （P=0.026）. In the experimental group, the adverse reactions during maintenance treatment were bone marrow suppression （36.6%）, liver and kidney dysfunction （40.0%）, hand foot syndrome （46.7%）, gastrointestinal reactions （60.0%）.Conclusion Capecitabine as the maintenance treatment regimen for three-negative breast cancer can effectively improve the patient’s symptoms, and delay the progress of the disease.

关 键 词：卡培他滨 复发 转移 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]